

## Board of Directors (Public)

### Item 4.4

**Subject:** Research & Innovation Strategy  
2015/16 – 2017/18

**Date of meeting:** 28<sup>th</sup> April 2015

**Prepared by:** Dr Mark Jackson, Director of Research & Informatics  
Dr Marga Perez-Casal, Head of Research & Innovation  
Dr Jay Wright, Clinical Lead for Research & Innovation

**Presented by:** Dr Jay Wright, Clinical Lead for Research & Innovation

**board  
report**

Data Quality Rating	BAF Ref	Impact on BAF Risk Rating?
Bronze	New risk added to 2015/16 BAF	None

### 1. Executive Summary

The purpose of this paper is to present the Trusts Research and Innovation Strategy for the period 2015/16 to 2017/18.

### 2. Background

The Trust has delivered the vast majority of objectives of the previous strategy. Progress has been the subject of annual reports to the Board of Directors, the last one being in October 2014.

The principal area of underperformance has been in our inability to attract external grant funding. This risk has been mitigated by strong performance in commercial research, and investment in two academic appointments shared with other institutions in our health economy to promote collaboration. That said, we have started 2015/16 well with Dr Stables advancing a new collaboration with Southampton University Hospital who will likely join ICMS in the very near future. Together, they have secured a £1.6m grant to deliver the RIPCORDER trial which will investigate whether the addition of the measurement of fractional flow reserve to diagnostic angiography alters management of patients with coronary heart disease. This income will be shared between the two institutions.

### 3. Issues

The strategy recognises our current research strengths, and also likely new fields of medicine that the Trust needs to seek engagement in research now to become market leaders in the future. It also addresses how we can become more successful in:

- Building a culture that promotes and supports research and innovation activity within the Trust
- Developing capacity and capability for research and innovation within the Trust

- Maximising opportunities for our patients to take part in research
- Maximising opportunities for research and innovation collaborations with external partners
- Ensuring effective governance of research & innovation

The development of innovation is a particular focus of the strategy as this area of activity is under-developed at LHCH, although our external reputation as an innovator is strong both regionally and nationally.

Additionally, this strategy covers the development of the Integrated Clinical Evaluation (ICE) Unit which we hope will be the sole focus of the Trust's capital fundraising campaign. This endeavour will be presented separately to the Board of Directors later in the year.

#### **4. Conclusion**

This strategy:

1. Recognises the importance of innovation for the Trust's future success, and ensures it receives appropriate management time accordingly.
2. Develops our established research strengths, and seeks new ones in accord with the Trusts clinical developments.
3. Invests appropriately in staff capability and knowledge to help keep our Trust at the cutting edge of service delivery.
4. Ensures communications are robust, allowing all who wish to take part to become involved.

#### **5. Recommendations**

The Board of Directors are asked to approve this strategy for implementation.